Exact Sciences (EXAS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
October 30, 2015 8:32 AM EDTRoth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00), following the company's 3Q earnings results and guidance. Management introduced 4Q volume guidance of 42k tests. EXAS also introduced 2016 volume and revenue guidance of 240k and... More
